Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05314179
Other study ID # HCC 21-265
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 13, 2022
Est. completion date June 2024

Study information

Verified date September 2023
Source University of Pittsburgh
Contact Joshua Plassmeyer, MS
Phone 412-648-6417
Email plassmeyerjm@upmc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The proposed program, "Doulas - AC" will provide Dignity, Legacy, Advocacy and Support for Advanced Cancer: Reimagined End of Life Care in the Black Community." The goals are to: 1) provide a community-based, trained companion to journey alongside the patient with advanced cancer, 2) to help the individual explore meaning and create legacy, 3); offer support and navigation for practical needs of illness (e.g., financial assistance for food and housing, accessing and affording medications, transportation); and 4) to provide support and connection for the bereaved family/friends, including facilitating community connections for routine health screenings and access to mental health services, as needed.


Description:

The patient will be contacted and consent will be obtained by telephone. Once consent is obtained, the doula will be contacted with the patient information. The doula will then contact the patient and determine how the 3 hours/week will be sent. The doula will be trained by the study PI. The protocols for patient engagement will be taught. At the conclusion of the training, the doula that successfully work with standardized patients will be asked to work through the protocols for each clinic visit. The options of emotional support, practical assistance, family support, and legacy building projects will be offered. The nature and type of visits will be determined by the patient and doula. A weekly plan will be implemented by the doula which may involve conversations, creating legacy projects, conversations with family and patients, and assistance with practical issues. Following completion of data collection, descriptive statistics will be utilized to evaluate % change in patient outcomes from baseline to 2 months and study completion. Implementation outcomes will be quantified.


Recruitment information / eligibility

Status Recruiting
Enrollment 5
Est. completion date June 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients diagnosed with Metastatic Breast Cancer 2. Participants must be of African American race 3. Participants must reside in or around Pittsburgh, Pennsylvania area Exclusion Criteria: 1. Inability to read or understand English

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
DOULA-AC 1
Doula and Patient will decide on details of engagement. The components to be included will be: 1) emotional support, 2)practical assistance, 3) family support, and/or 4)legacy building projects as per study protocols. The nature and type of visits will be determined by the patient and doula.

Locations

Country Name City State
United States UPMC Hillman Cancer Center Pittsburgh Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
University of Pittsburgh

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Interpersonal Support Evaluation List (ISEL) The Interpersonal Support Evaluation List (ISEL) is a 40-item scale comprised of four subscales: 1.) Tangible Support; 2.) Belonging Support; 3.) Self-esteem Support; 4.) Appraisal Support. Items are rated by participants on how true or false they believe the statements are for themselves. Answers are given on a 4-point scale ranging from 0-3: definitely false (0), probably false (1), probably true (2), definitely true (3). The ISEL is scored by summing the items to create an overall score that indicates a participant's perceived level of social support. Total scores (total of all subscales) range from 0-120. Higher ISEL scores indicate greater ability to endure stressful experiences and greater perceived social support. Baseline, up to 6 months
Primary Change in Hospital Anxiety and Depression Scale (HADS) The HADS questionnaire is a self-assessment questionnaire detecting states of anxiety and depression that includes 7 items each for depression and anxiety subscales. Scoring for each item ranges from 0 - 3. Scores of 3 for a single item denotes highest anxiety or depression level. Total overall scores (total of all subscales) range from 0 - 21. A total score of 8 or more points out of a possible 21 indicates considerable symptoms of anxiety or depression. Baseline, up to 6 months
Primary Change in Patient-Reported Outcomes Measurement Information System (PROMIS-29) Questionnaire The Patient-Reported Outcomes Measurement Information System (PROMIS-29) is a short form assessment that uses a single 0-10 numeric pain rating item and seven health domains using four items each. The seven domains included Depression, Anxiety, Physical Function, Pain Interference, Fatigue, Sleep Disturbance, and Ability to Participate in Social Roles and Activities. It also includes plus one pain intensity question. Total raw scores range from 0 - 290. Higher PROMIS scores indicate more severe effect of pain on domain items and on quality of life. Baseline, up to 6 months
See also
  Status Clinical Trial Phase
Withdrawn NCT04872608 - A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer Phase 1
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Completed NCT02506556 - Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer Phase 2
Recruiting NCT05534438 - A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer Phase 2
Recruiting NCT03368729 - Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer Phase 1/Phase 2
Completed NCT04103853 - Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer Phase 1
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Active, not recruiting NCT03147287 - Palbociclib After CDK and Endocrine Therapy (PACE) Phase 2
Not yet recruiting NCT06062498 - Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer Phase 2
Recruiting NCT05383196 - Onvansertib + Paclitaxel In TNBC Phase 1/Phase 2
Recruiting NCT04095390 - A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer Phase 2
Active, not recruiting NCT04432454 - Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Phase 2
Recruiting NCT03323346 - Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer Phase 2
Recruiting NCT05744375 - Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab Phase 2
Completed NCT02924883 - A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy Phase 2
Completed NCT01942135 - Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) Phase 3
Completed NCT01881230 - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Phase 2/Phase 3
Active, not recruiting NCT04448886 - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Phase 2
Completed NCT01401959 - Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy Phase 2
Terminated NCT04720664 - Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer Phase 2